Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs.

Zapata JM, Perez-Chacon G, Carr-Baena P, Martinez-Forero I, Azpilikueta A, Otano I, Melero I.

Front Immunol. 2018 Nov 15;9:2618. doi: 10.3389/fimmu.2018.02618. eCollection 2018. Review.

2.

Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?

Weigelin B, Bolaños E, Rodriguez-Ruiz ME, Martinez-Forero I, Friedl P, Melero I.

Cancer Immunol Immunother. 2016 May;65(5):493-7. doi: 10.1007/s00262-016-1818-5. Epub 2016 Mar 12.

PMID:
26970765
3.

Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.

Weigelin B, Bolaños E, Teijeira A, Martinez-Forero I, Labiano S, Azpilikueta A, Morales-Kastresana A, Quetglas JI, Wagena E, Sánchez-Paulete AR, Chen L, Friedl P, Melero I.

Proc Natl Acad Sci U S A. 2015 Jun 16;112(24):7551-6. doi: 10.1073/pnas.1506357112. Epub 2015 Jun 1.

4.

Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolaños E, Jure-Kunkel M, Gütgemann I, Melero I.

Clin Cancer Res. 2013 Nov 15;19(22):6151-62. doi: 10.1158/1078-0432.CCR-13-1189. Epub 2013 Sep 12.

5.

T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.

Martinez-Forero I, Azpilikueta A, Bolaños-Mateo E, Nistal-Villan E, Palazon A, Teijeira A, Perez-Chacon G, Morales-Kastresana A, Murillo O, Jure-Kunkel M, Zapata JM, Melero I.

J Immunol. 2013 Jun 15;190(12):6694-706. doi: 10.4049/jimmunol.1203010. Epub 2013 May 20.

6.

Dynamic cross-regulation of antigen-specific effector and regulatory T cell subpopulations and microglia in brain autoimmunity.

Martinez-Pasamar S, Abad E, Moreno B, Velez de Mendizabal N, Martinez-Forero I, Garcia-Ojalvo J, Villoslada P.

BMC Syst Biol. 2013 Apr 26;7:34. doi: 10.1186/1752-0509-7-34.

7.

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.

Palazón A, Martínez-Forero I, Teijeira A, Morales-Kastresana A, Alfaro C, Sanmamed MF, Perez-Gracia JL, Peñuelas I, Hervás-Stubbs S, Rouzaut A, de Landázuri MO, Jure-Kunkel M, Aragonés J, Melero I.

Cancer Discov. 2012 Jul;2(7):608-23. doi: 10.1158/2159-8290.CD-11-0314. Epub 2012 Jun 19.

8.

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

Martinez Forero I, Okada H, Topalian SL, Gajewski TF, Korman AJ, Melero I.

J Transl Med. 2012 May 28;10:108. doi: 10.1186/1479-5876-10-108.

9.

CD137 on inflamed lymphatic endothelial cells enhances CCL21-guided migration of dendritic cells.

Teijeira Á, Palazón A, Garasa S, Marré D, Aubá C, Rogel A, Murillo O, Martínez-Forero I, Lang F, Melero I, Rouzaut A.

FASEB J. 2012 Aug;26(8):3380-92. doi: 10.1096/fj.11-201061. Epub 2012 May 16.

PMID:
22593548
10.

Dendritic cells take up and present antigens from viable and apoptotic polymorphonuclear leukocytes.

Alfaro C, Suarez N, Oñate C, Perez-Gracia JL, Martinez-Forero I, Hervas-Stubbs S, Rodriguez I, Perez G, Bolaños E, Palazon A, Sanmamed MF, Morales-Kastresana A, Gonzalez A, Melero I.

PLoS One. 2011;6(12):e29300. doi: 10.1371/journal.pone.0029300. Epub 2011 Dec 20.

11.

Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients.

Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, Gonzalez A, Rodriguez I, Bolaños E, Hervás-Stubbs S, Perez-Calvo J, Benito A, Peñuelas I, Vigil C, Richter J, Martinez-Forero I, Melero I.

J Immunol. 2011 Dec 1;187(11):6130-42. doi: 10.4049/jimmunol.1102209. Epub 2011 Nov 2.

12.

SimB16: modeling induced immune system response against B16-melanoma.

Pappalardo F, Martinez Forero I, Pennisi M, Palazon A, Melero I, Motta S.

PLoS One. 2011;6(10):e26523. doi: 10.1371/journal.pone.0026523. Epub 2011 Oct 19.

13.

Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in Multiple Sclerosis.

Vélez de Mendizábal N, Carneiro J, Solé RV, Goñi J, Bragard J, Martinez-Forero I, Martinez-Pasamar S, Sepulcre J, Torrealdea J, Bagnato F, Garcia-Ojalvo J, Villoslada P.

BMC Syst Biol. 2011 Jul 15;5:114. doi: 10.1186/1752-0509-5-114.

14.

Carcinoma-derived interleukin-8 disorients dendritic cell migration without impairing T-cell stimulation.

Alfaro C, Suárez N, Martínez-Forero I, Palazón A, Rouzaut A, Solano S, Feijoo E, Gúrpide A, Bolaños E, Erro L, Dubrot J, Hervás-Stubbs S, Gonzalez A, Perez-Gracia JL, Melero I.

PLoS One. 2011 Mar 14;6(3):e17922. doi: 10.1371/journal.pone.0017922.

15.

International symposium on CTL and immunostimulation, Pamplona (Spain), October 26th and 27th 2010.

Ochoa MC, Hervas-Stubbs S, Palazon A, Martinez-Forero I, Berraondo P, Sarobe P, Melcher A, Melero I.

Cancer Immunol Immunother. 2011 May;60(5):753-6. doi: 10.1007/s00262-011-1000-z. Epub 2011 Mar 5. No abstract available.

PMID:
21380561
16.

Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.

Palazón A, Teijeira A, Martínez-Forero I, Hervás-Stubbs S, Roncal C, Peñuelas I, Dubrot J, Morales-Kastresana A, Pérez-Gracia JL, Ochoa MC, Ochoa-Callejero L, Martínez A, Luque A, Dinchuk J, Rouzaut A, Jure-Kunkel M, Melero I.

Cancer Res. 2011 Feb 1;71(3):801-11. doi: 10.1158/0008-5472.CAN-10-1733. Epub 2011 Jan 25.

17.

Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α.

Rouzaut A, Garasa S, Teijeira A, González I, Martinez-Forero I, Suarez N, Larrea E, Alfaro C, Palazón A, Dubrot J, Hervás-Stubbs S, Melero I.

Eur J Immunol. 2010 Nov;40(11):3054-63. doi: 10.1002/eji.201040523. Epub 2010 Oct 27.

18.

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo.

Suarez N, Alfaro C, Dubrot J, Palazon A, Bolaños E, Erro L, Hervas-Stubbs S, Martinez-Forero I, Morales-Kastresana A, Martin-Algarra S, Sangro B, Lecanda F, Perez-Gracia JL, Gonzalez A, Melero I.

Int J Cancer. 2011 Jul 15;129(2):374-86. doi: 10.1002/ijc.25681. Epub 2010 Nov 16.

19.

Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

Perez-Gracia JL, Berraondo P, Martinez-Forero I, Alfaro C, Suarez N, Gurpide A, Sangro B, Hervas-Stubbs S, Ochoa C, Melero JA, Melero I.

Immunotherapy. 2009 Sep;1(5):845-53. doi: 10.2217/imt.09.51. Review.

PMID:
20636027
20.

Steady state detection of chemical reaction networks using a simplified analytical method.

Martínez-Forero I, Peláez-López A, Villoslada P.

PLoS One. 2010 Jun 3;5(6):e10823. doi: 10.1371/journal.pone.0010823.

21.

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ.

Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, Morales-Kastresana A, Romero-Trevejo JL, Ochoa MC, Hervás-Stubbs S, Prieto J, Jure-Kunkel M, Chen L, Melero I.

Cancer Immunol Immunother. 2010 Aug;59(8):1223-33. doi: 10.1007/s00262-010-0846-9. Epub 2010 Mar 25.

PMID:
20336294
22.

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.

Dubrot J, Palazón A, Alfaro C, Azpilikueta A, Ochoa MC, Rouzaut A, Martinez-Forero I, Teijeira A, Berraondo P, Le Bon A, Hervás-Stubbs S, Melero I.

Int J Cancer. 2011 Jan 1;128(1):105-18. doi: 10.1002/ijc.25333.

23.

A semi-physiological-based pharmacokinetic/pharmacodynamic model to describe the effects of topotecan on b-lymphocyte lineage cells.

Vélez de Mendizábal N, Martínez-Forero I, Garrido MJ, Bandrés E, García-Foncillas J, Segura C, Trocóniz IF.

Pharm Res. 2010 Mar;27(3):431-41. doi: 10.1007/s11095-009-0025-x. Epub 2010 Jan 26.

PMID:
20101520
24.

Lysine 63 polyubiquitination in immunotherapy and in cancer-promoting inflammation.

Martinez-Forero I, Rouzaut A, Palazon A, Dubrot J, Melero I.

Clin Cancer Res. 2009 Nov 15;15(22):6751-7. doi: 10.1158/1078-0432.CCR-09-1225. Epub 2009 Nov 3. Review.

25.

Palettes of vaccines and immunostimulatory monoclonal antibodies for combination.

Melero I, Martinez-Forero I, Dubrot J, Suarez N, Palazón A, Chen L.

Clin Cancer Res. 2009 Mar 1;15(5):1507-9. doi: 10.1158/1078-0432.CCR-08-2931. Epub 2009 Feb 24.

26.

Pharmacogenomics of multiple sclerosis: in search for a personalized therapy.

Martinez-Forero I, Pelaez A, Villoslada P.

Expert Opin Pharmacother. 2008 Dec;9(17):3053-67. doi: 10.1517/14656560802515553 . Review.

PMID:
19006478
27.

IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.

Martinez-Forero I, Garcia-Munoz R, Martinez-Pasamar S, Inoges S, Lopez-Diaz de Cerio A, Palacios R, Sepulcre J, Moreno B, Gonzalez Z, Fernandez-Diez B, Melero I, Bendandi M, Villoslada P.

Eur J Immunol. 2008 Feb;38(2):576-86. doi: 10.1002/eji.200737271.

28.

A network analysis of the human T-cell activation gene network identifies JAGGED1 as a therapeutic target for autoimmune diseases.

Palacios R, Goni J, Martinez-Forero I, Iranzo J, Sepulcre J, Melero I, Villoslada P.

PLoS One. 2007 Nov 21;2(11):e1222.

Supplemental Content

Loading ...
Support Center